Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 8Breast 7Gastrointestinal 4CNS 2Tumor-Agnostic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 163Specimen Handling 135enzalutamide 126Nivolumab 124Gemcitabine 99Docetaxel 96Radiosurgery 92Prednisone 85Androgen Antagonists 82Abiraterone Acetate 81Radiotherapy 75apalutamide 68Cisplatin 65darolutamide 63Ipilimumab 63Biopsy 60abiraterone 58Carboplatin 56cabozantinib 55Leuprolide 53enfortumab vedotin 49Radiation 48Pluvicto 45Standard of Care 44atezolizumab 40Surveys and Questionnaires 39acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
patritumab deruxtecan × Genitourinary × 1 year × Clear all
NCT06172478 2026-05-15

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

Phase 2 Recruiting
740 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡